Skip to main content

Table 1 Selection from entry cohort to samples of analysis

From: The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients

Sample

Cohort 1996–97

Cohort 2003–04

Total

 

N

%

N

%

N

%

Entry cohort

389

100,0

488

100,0

877

100,0

./. loss-to-follow up

0

0,0

17

3,5

17

1,9

./. No stage information availablea

1

0,3

2

0,4

3

0,3

./. Stage 0b

22

5,7

33

6,8

55

6,3

./. Mx, M1c

20

5,1

26

5,3

46

5,2

./. Missings on marginal resectiond

1

0,3

12

2,5

13

1,5

Institutional-invasive sample

345

88,7

398

81,6

743

84,7

./. Non-residents

107

27,5

132

27,0

239

27,3

Regional-invasive sample

238

61,2

266

54,5

504

57,5

  1. Legend: arefers to non-assessable stage information, bexcludes non tissue invasive tumors (pTis), cexcluded all non-assessable metastasis status or distant metastasis, dpatients without any information are excluded